EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis

M. J L Peters, D. P M Symmons, D. McCarey, B. A C Dijkmans, P. Nicola, T. K. Kvien, I. B. McInnes, H. Haentzschel, M. A. Gonzalez-Gay, S. Provan, A. Semb, P. Sidiropoulos, G. Kitas, Y. M. Smulders, M. Soubrier, Z. Szekanecz, N. Sattar, M. T. Nurmohamed

    Research output: Contribution to journalArticlepeer-review

    Abstract

    Objectives: To develop evidence-based EULAR recommendations for cardiovascular (CV) risk management in patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic arthritis (PsA). Methods: A multidisciplinary expert committee was convened as a task force of the EULAR Standing Committee for Clinical Affairs (ESCCA), comprising 18 members including rheumatologists, cardiologists, internists and epidemiologists, representing nine European countries. Problem areas and related keywords for systematic literature research were identified. A systematic literature research was performed using MedLine, Embase and the Cochrane library through to May 2008. Based on this literature review and in accordance with the EULAR's "standardised operating procedures", the multidisciplinary steering committee formulated evidencebased and expert opinion-based recommendations for CV risk screening and management in patients with inflammatory arthritis. Results: Annual CV risk assessment using national guidelines is recommended for all patients with RA and should be considered for all patients with AS and PsA. Any CV risk factors identified should be managed according to local guidelines. If no local guidelines are available, CV risk management should be carried out according to the SCORE function. In addition to appropriate CV risk management, aggressive suppression of the inflammatory process is recommended to further lower the CV risk. Conclusions: Ten recommendations were made for CV risk management in patients with RA, AS and PsA. The strength of the recommendations differed between RA on the one hand, and AS and PsA, on the other, as evidence for an increased CV risk is most compelling for RA.
    Original languageEnglish
    Pages (from-to)325-331
    Number of pages6
    JournalAnnals of the rheumatic diseases
    Volume69
    Issue number2
    DOIs
    Publication statusPublished - Feb 2010

    Fingerprint

    Dive into the research topics of 'EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis'. Together they form a unique fingerprint.

    Cite this